PPARG and familial pancreatic carcinoma: Selective PPARγ ligands inhibit pancreatic cancer cell growth in a dose-dependent manner and reduce the invasiveness of the tumor cells, suggesting a potential role for these agents in the adjuvant treatment of pancreatic cancer [41].